Clinical trial
Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
NCT00460460 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00460460 |
|---|---|
| Title | Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies |
| Official title | A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | AZD4877 |
| Enrollment | 75 |
| Start date | Mar 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Apr 16, 2007 |
| Last update posted | Jan 25, 2011 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: